SCHEMBL1082055

SCHEMBL1082055

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(N)nc2c(-c2cnn(C)c2)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 9/20 0.60
KDR P35968 7/20 0.60
TEK Q02763 5/20 0.60
MAPK14 Q16539 4/20 0.60
JAK3 P52333 3/20 0.60
CSF1R P07333 4/20 0.57
DDR2 Q16832 4/20 0.57
FGFR1 P11362 2/20 0.56
KIT P10721 4/20 0.52
PDGFRB P09619 2/20 0.51
BRAF P15056 4/20 0.50
ABL1 P00519 2/20 0.50
SRC P12931 2/20 0.50
BMX P51813 2/20 0.50
FYN P06241 1/20 0.50
YES1 P07947 1/20 0.50
LYN P07948 1/20 0.50
HCK P08631 1/20 0.50
FGR P09769 1/20 0.50
CSK P41240 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149466 0.94 KDR (0.60) LCKKDRTEKMAPK14JAK3
SCHEMBL1077958 0.94 LCK (0.57) LCKKDRTEKMAPK14JAK3
SCHEMBL1078762 0.93 LCK (0.55) LCKKDRTEKMAPK14JAK3
SCHEMBL1149308 0.91 DDR2 (0.59) LCKKDRTEKMAPK14JAK3
SCHEMBL1077857 0.91 LCK (0.58) LCKKDRTEKMAPK14JAK3
SCHEMBL1079435 0.91 LCK (0.61) LCKKDRTEKMAPK14JAK3
SCHEMBL1149236 0.90 DDR2 (0.57) LCKKDRTEKMAPK14JAK3
SCHEMBL1148998 0.89 LCK (0.67) LCKKDRTEKMAPK14JAK3
SCHEMBL1149446 0.89 LCK (0.67) LCKKDRTEKMAPK14JAK3
SCHEMBL1079343 0.88 LCK (0.45) LCKKDRTEKMAPK14JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 LCK 3187/4885KDR 896/4885TEK 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.